These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement. But to the ears of other investors, the same two words imply a risk they'd rather not think about. Let's dive in and sort out what's going on, as well as which of these two perspectives is more relevant for those considering a purchase of this stock today. This is a good omen Intellia makes gene therapies for genetic illnesses like hereditary angioedema (HAE). Some of those therapies, like NTLA-2002, one of its investigational medicines for HAE, entail editing the patient's genes directly so as to correct the inborn errors that cause illness. Such approaches are intended to be attempted only once per patient. But if they work as intended, the impact is potentially sufficient to make them symptom-free, potentially for the rest of their lives. Such patients might still technically have the disorde
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.MarketBeat
- Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024GlobeNewswire
- Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics Names Brian Goff to its Board of Directors [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 5/9/24 - Beat
NTLA
Sec Filings
- 6/20/24 - Form 4
- 6/17/24 - Form 3
- 6/17/24 - Form 4
- NTLA's page on the SEC website